Immix Biopharma (IMMX) announced a “class-leading” safety profile for sterically-optimized CAR-T NXC-201, including absence of neurotoxicity of any grade in low-volume disease to-date, laying a foundation for potential future indication expansion. “We are singularly focused on completing NEXICART-2 for BLA submission, where we are accelerating progress. Separately and subsequently, for potential future expansion directions, we believe NXC-201 will be able to address a range of immune-mediated and other serious diseases,” said Ilya Rachman, M.D., Ph.D., CEO of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Our near-term efforts are laser- focused on our path to NEXICART-2 BLA submission for FDA approval.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX:
- Immix Biopharma’s Strategic Expansion and Promising Trial Results Reinforce Buy Rating
- Immix Biopharma announces accelerated NEXICART-2 trial progress
- Immix Biopharma Holds Annual Meeting, Elects Directors
- Promising Interim Results from NEXICART-2 Trial Support Buy Rating for NXC-201
- Immix Biopharma files $13.45M common stock ATM offering